Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.

Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Smakov R, Bellido M, Cabrera-Garcia A, Gziri MM, Halaska MJ, Ottevanger PB, Van Calsteren K, O'Laughlin A, Polushkina E, Van Dam L, Avivi I, Vandenberghe P, Woei-A-Jin FJSH, Amant F; International Network on Cancer, Infertility and Pregnancy.

Lancet Haematol. 2019 Sep 26. pii: S2352-3026(19)30195-4. doi: 10.1016/S2352-3026(19)30195-4. [Epub ahead of print]

PMID:
31564649
2.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review.

PMID:
31292114
3.

Tyrosine kinase inhibitor levels matter in treating chronic GVHD.

van der Wagen L, Janssen J, Raijmakers R, Petersen E, de Witte M, de Jong N, Bellido M, Meijer E, Bär B, Jan Boelens J, Huitema A, Kuball J.

Bone Marrow Transplant. 2019 Jul;54(7):1141-1144. doi: 10.1038/s41409-018-0429-5. Epub 2019 Jan 16. No abstract available.

PMID:
30651587
4.

VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity.

Palomares B, Ruiz-Pino F, Navarrete C, Velasco I, Sánchez-Garrido MA, Jimenez-Jimenez C, Pavicic C, Vazquez MJ, Appendino G, Bellido ML, Calzado MA, Tena-Sempere M, Muñoz E.

Sci Rep. 2018 Oct 31;8(1):16092. doi: 10.1038/s41598-018-34259-0.

5.

Triterpenoid Hydroxamates as HIF Prolyl Hydrolase Inhibitors.

Minassi A, Rogati F, Cruz C, Prados ME, Galera N, Jinénez C, Appendino G, Bellido ML, Calzado MA, Caprioglio D, Muñoz E.

J Nat Prod. 2018 Oct 26;81(10):2235-2243. doi: 10.1021/acs.jnatprod.8b00514. Epub 2018 Oct 10.

PMID:
30350996
6.

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis.

García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA, Muñoz E.

Biochem Pharmacol. 2018 Nov;157:304-313. doi: 10.1016/j.bcp.2018.07.047. Epub 2018 Aug 2.

PMID:
30076848
7.

Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido M, Fernández-Ruiz J, Muñoz E, de Lago E.

Biochem Pharmacol. 2018 Nov;157:217-226. doi: 10.1016/j.bcp.2018.07.049. Epub 2018 Aug 1.

PMID:
30076846
8.

Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.

van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J.

Bone Marrow Transplant. 2018 Oct;53(10):1255-1262. doi: 10.1038/s41409-018-0158-9. Epub 2018 Mar 16.

PMID:
29549292
9.

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.

Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E.

J Neuroinflammation. 2018 Mar 1;15(1):64. doi: 10.1186/s12974-018-1103-y.

10.

Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.

Nadal X, Del Río C, Casano S, Palomares B, Ferreiro-Vera C, Navarrete C, Sánchez-Carnerero C, Cantarero I, Bellido ML, Meyer S, Morello G, Appendino G, Muñoz E.

Br J Pharmacol. 2017 Dec;174(23):4263-4276. doi: 10.1111/bph.14019. Epub 2017 Nov 2.

11.

Electrophilic Triterpenoid Enones: A Comparative Thiol-Trapping and Bioactivity Study.

Del Prete D, Taglialatela-Scafati O, Minassi A, Sirignano C, Cruz C, Bellido ML, Muñoz E, Appendino G.

J Nat Prod. 2017 Aug 25;80(8):2276-2283. doi: 10.1021/acs.jnatprod.7b00271. Epub 2017 Jul 28.

PMID:
28753294
12.

Bacteraemia due to non-ESBL-producing Escherichia coli O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes.

Morales-Barroso I, López-Cerero L, Molina J, Bellido M, Navarro MD, Serrano L, González-Galán V, Praena J, Pascual A, Rodríguez-Baño J.

Int J Antimicrob Agents. 2017 Apr;49(4):498-502. doi: 10.1016/j.ijantimicag.2016.12.013. Epub 2017 Feb 28.

PMID:
28257756
13.

VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.

Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

Sci Rep. 2016 Jul 19;6:29789. doi: 10.1038/srep29789.

14.

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways.

del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E.

Sci Rep. 2016 Feb 18;6:21703. doi: 10.1038/srep21703.

15.

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O.

Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z.

16.

Production of functional active human growth factors in insects used as living biofactories.

Dudognon B, Romero-Santacreu L, Gómez-Sebastián S, Hidalgo AB, López-Vidal J, Bellido ML, Muñoz E, Escribano JM.

J Biotechnol. 2014 Aug 20;184:229-39. doi: 10.1016/j.jbiotec.2014.05.030. Epub 2014 Jun 7.

PMID:
24915129
17.

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.

Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, Bellido ML, Muñoz E, Guaza C.

PLoS One. 2014 Apr 11;9(4):e94733. doi: 10.1371/journal.pone.0094733. eCollection 2014.

18.

Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications.

López-Cerero L, Navarro MD, Bellido M, Martín-Peña A, Viñas L, Cisneros JM, Gómez-Langley SL, Sánchez-Monteseirín H, Morales I, Pascual A, Rodríguez-Baño J.

J Antimicrob Chemother. 2014 Mar;69(3):809-14. doi: 10.1093/jac/dkt405. Epub 2013 Oct 11.

PMID:
24123431
19.

Within-lineage variability of ST131 Escherichia coli isolates from humans and companion animals in the south of Europe.

Pomba C, López-Cerero L, Bellido M, Serrano L, Belas A, Couto N, Cavaco-Silva P, Rodríguez-Baño J, Pascual A.

J Antimicrob Chemother. 2014 Jan;69(1):271-3. doi: 10.1093/jac/dkt343. Epub 2013 Sep 10. No abstract available.

PMID:
24022069
20.

FaGAST2, a strawberry ripening-related gene, acts together with FaGAST1 to determine cell size of the fruit receptacle.

Moyano-Cañete E, Bellido ML, García-Caparrós N, Medina-Puche L, Amil-Ruiz F, González-Reyes JA, Caballero JL, Muñoz-Blanco J, Blanco-Portales R.

Plant Cell Physiol. 2013 Feb;54(2):218-36. doi: 10.1093/pcp/pcs167. Epub 2012 Dec 11.

PMID:
23231876

Supplemental Content

Loading ...
Support Center